论文部分内容阅读
目的:探讨骨肉瘤组组织SRp20蛋白表达情况及其临床意义。方法:应用Max Vision免疫组化方法检测64例骨肉瘤组织和18例骨软骨瘤组织SRp20蛋白表达情况,并分析与临床病理参数之间的关系。结果:骨肉瘤组织和骨软骨瘤组织中,SRp20胞核阳性表达率分别为14.1%(9/64)和0(0/18),P=0.195;而骨肉瘤组织和骨软骨瘤组织中,SRp20细胞质阳性表达率分别为73.4%(47/64)和5.6%(1/18),P<0.001。在骨肉瘤组织中,SRp20的细胞质阳性表达与骨肉瘤的恶性程度(P=0.002)、Enneking分期(P=0.001)以及5年生存率(P=0.023)相关。结论:SRp20细胞质表达与骨肉瘤患者的不良预后相关,可能成为预测患者预后情况的靶点。
Objective: To investigate the expression of SRp20 protein in osteosarcoma and its clinical significance. Methods: Max Vision immunohistochemical method was used to detect the expression of SRp20 protein in 64 osteosarcoma tissues and 18 osteochondroma tissues. The relationship between SRp20 expression and clinicopathological parameters was analyzed. Results: The positive rates of SRp20 nuclei in osteosarcoma and osteochondroma were 14.1% (9/64) and 0 (0/18), respectively, P = 0.195. In osteosarcoma and osteochondroma tissues, The positive expression rates of SRp20 in cytoplasm were 73.4% (47/64) and 5.6% (1/18) respectively, P <0.001. The positive expression of SRp20 in osteosarcoma correlated with the malignancy of osteosarcoma (P = 0.002), Enneking stage (P = 0.001) and 5-year survival rate (P = 0.023). Conclusion: The expression of SRp20 in cytoplasm may be related to poor prognosis of patients with osteosarcoma and may be the target of predicting the prognosis of patients.